Shots:

• Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to be completed in Q1’21
• The acquisition expands Haemonetics’ blood transfusion and loss management offerings and enhance its penetration into the large and growing interventional cardiology and electrophysiology markets
• Cardiva's portfolio includes two catheter-based vascular access site closure devices used to help seal up access sites following minimally invasive interventions and diagnostic procedures. Both devices employ a collapsible disc in different sizes to deliver a collagen patch to achieve hemostasis

 ­ Ref: PRNewswire| Image: Cardiva